Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (42 ops.)
Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing
Filing timeline
BuySaleCedric Francois
Insider track record
Disclosed buys
0
Disclosed sells
42
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Cedric Francois: trading record in brief
Cedric Francois, listed as chief executive, appears in our data through filings on Apellis Pharmaceuticals, Inc. shares, published by SEC (Form 4). The record holds 83 filings, for trades running from 7 May 2018 to 14 May 2026.
Every open-market trade on record is a sale: 42 sales worth €12.8M. The rest of the record consists of 12 share grants and 20 option exercises. So far in 2026, the count stands at no purchases and 3 sales.
The newest entry dates from 14 May 2026: a transaction, in Apellis Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Cedric Francois
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations41 total
425,968 sharesCommon StockSEC:0001193125-26-224579:0
64,869 shares0Common StockSEC:0001193125-26-106090:0
8,840 shares@ US$3.760.3% of flowCommon StockSEC:0001492422-26-000081:0
195,952 shares0Common StockSEC:0001492422-26-000071:0
27,192 shares@ US$21.76545.3% of flowCommon StockSEC:0001492422-26-000057:0
8,182 shares@ US$19.79291.4% of flowCommon StockSEC:0001492422-26-000041:0
10,186 shares@ US$22.18722.0% of flowCommon StockSEC:0001492422-26-000028:0
175,037 shares@ US$28.1948.3% of flowCommon StockSEC:0001193125-25-192797:0
8,997 shares@ US$4.316.7% of flowCommon StockSEC:0001127602-25-019413:0
65,203 shares@ US$4.3148.1% of flowCommon StockSEC:0001127602-25-019265:0
2,824 shares@ US$29.52361.8% of flowCommon StockSEC:0001127602-25-002375:0
13,551 shares@ US$30.42558.7% of flowCommon StockSEC:0001127602-25-001837:0
6,007 shares@ US$29.95823.8% of flowCommon StockSEC:0001127602-25-001620:0
130,662 shares0Common StockSEC:0001127602-25-001620:1
6,247 shares@ US$28.70213.9% of flowCommon StockSEC:0001127602-25-001197:0
182,146 shares0Common StockSEC:0000950170-24-120214:0
50,000 shares@ US$3.763.8% of flowCommon StockSEC:0001127602-24-008505:0
3,962 shares@ US$67.76695.5% of flowCommon StockSEC:0001127602-24-004718:0
2,843 shares@ US$64.13823.7% of flowCommon StockSEC:0001127602-24-002740:0
13,431 shares@ US$64.99617.7% of flowCommon StockSEC:0001127602-24-001970:0
72,094 shares0Common StockSEC:0001127602-24-001431:0
5,000 shares@ US$48.804.9% of flowCommon StockSEC:0000950170-23-065613:0
150,000 shares0Common StockSEC:0000950170-23-049003:0
300,000 shares@ US$2.6716.3% of flowCommon StockSEC:0001127602-23-023560:0
20,000 shares0Common StockSEC:0000950170-23-024276:0
25 of 41 declarations
